Compare ADMA Biologics Inc (ADMA) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs JPMorgan Chase & Co — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while JPMorgan Chase & Co trades at $331.08 (market cap $908.94B). The key difference: JPMorgan Chase & Co is far larger — about 426.7× ADMA Biologics Inc's market cap, and JPMorgan Chase & Co pays a 1.77% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | JPM | |
|---|---|---|
Market Cap | $2.13B | $908.94B |
Sector | Health | Financials |
52-Week High | $20.38 | $339.22 |
52-Week Low | $7.60 | $282.78 |
Enterprise Value | $2.20B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
JPMorgan Chase & Co. (JPM) trades at $330.62, down 2.1% on the day, with technical indicators showing a bullish trend and strong support at $337. The company reported $181.85B revenue in 2025 with a net income margin of 31.61%, though earnings have been mixed with a recent miss in Q4 2025. Analyst consensus remains positive with a $360.38 price target, while CEO Jamie Dimon's recent shareholder letter highlighted economic risks.
JPM offers solid fundamentals with a P/E of 16.24 and ROE of 17.03%, but faces headwinds from geopolitical tensions and cybersecurity concerns. The stock's upside potential is supported by institutional buying and strong technicals, though investors should monitor net cash flow trends and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
